Abstract 2297P
Background
Upper tract urothelial carcinoma (UTUC) accounts for 5%-10% of all urothelial malignancies. And the incidence of UTUC in China is much higher than that in European and American countries, accounting for about 31%. Approximately two-thirds of patients have invasive disease at diagnosis. However, little research has been done on UTUCs.
Methods
To better understand the pathogenesis of UTUC and provide references for its diagnosis and treatment, we conducted a Weighted Correlation Network Analysis (WGCNA) involving the RNA sequencing data of 27 UTUC patients. Multiple linear regression models were used to explore the association between gene modules and clinical indicators. We then imported related modules into Cytoscape. to screen hub genes. Additionally, we performed RNA differential expression analysis, exon mutation analysis, and looked at mutations in hub genes. Enrichment analysis was then conducted based on differentially expressed genes to discover potential pathways regulating UTUC. Finally, bladder cancer data in TCGA database was used to verify the hub genes.
Results
We classified the genes into 31 modules by unsupervised clustering, with 4 modules (FDR<0.05) significantly associated with tumor infiltration. Then 9 potential biomarkers, including MSRB3, HSPB2, SCRG1, SYNPO2, FXYD1, PLXNA4, CD163, IFFO1, and FPR3, were discovered by importing these 4 modules into Cytoscape software. Differential expression analysis showed that except for the FPR3 gene, the remaining 8 genes were under expressed in UTUC. This has also been verified in public databases. Meanwhile, SNP mutation occurred in MSRB3, SYNPO2, and PLXNA4 genes. Functional enrichment analysis revealed that differentially expressed genes regulate UTUC through pathways such as cell adhesion, transmembrane receptor protein kinase activity, cGMP-PKG signaling pathway, p53 signaling pathway, and cardiomyocyte adrenergic signaling pathway.
Conclusions
Although these 9 genes are new and significant genes in UTUC, they have been proved in public databases. Our results not only promote our understanding of the relationship between the transcriptome and clinical data in UTUC but will also guide the development of targeted molecular therapy for UTUC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Device Regulatory Research and Evaluation Center.
Funding
Medical Device Regulatory Research and Evaluation Center.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2252P - KRAS G12C inhibition using MRTX849: A novel radio-sensitizing partner
Presenter: Marina Milic
Session: Poster session 08
2253P - RAS-precision medicine trans-atlantic partnership: Comparative analysis of KRAS codon 12 and 13 mutations in non-small cell lung cancer
Presenter: Helen Adderley
Session: Poster session 08
2254P - Persisting RAS addiction: A therapeutic vulnerability in the context of KRAS G12C inhibitor resistance
Presenter: George Morrissey
Session: Poster session 08
2255P - Clinicogenomic landscapes and hallmarks of KRAS amplification in human cancers
Presenter: Biagio Ricciuti
Session: Poster session 08
2256P - The microenvironment of normal mucosa could predict recurrence in the stage II/III colorectal cancer: Multicenter, multiomics study
Presenter: Yeonghak Bang
Session: Poster session 08
2257P - Stereotactic body radiation therapy and atezolizumab combination: Results of the international multi-centre SABR-PDL1 phase II trial colorectal cohort
Presenter: Antonin Levy
Session: Poster session 08
2258P - Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: Drug screen optimization and correlation with patient response
Presenter: Lidwien Smabers
Session: Poster session 08
2259P - An artificial neural network system to predict the fraction of type I polarized macrophage
Presenter: Tongji Xie
Session: Poster session 08
2260P - Berberine associated to SGLT-2i exerts synergistic cardioprotective effects in cardiac cells exposed to the HER2-blocking agent trastuzumab through pAMPK activation and reduction in Interleukin-6 levels
Presenter: Andrea Paccone
Session: Poster session 08
2261P - A head-to-head comparison for detecting PIK3CA mutations in circulating tumor DNA of advanced HR+/HER2- breast cancer patients
Presenter: Nadia Dandachi
Session: Poster session 08